Brokerages Set Adaptimmune Therapeutics plc (NASDAQ:ADAP) Price Target at $2.18

Adaptimmune Therapeutics plc (NASDAQ:ADAP) has received a consensus rating of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $2.18.

A number of equities research analysts recently weighed in on ADAP shares. Wells Fargo & Company lowered their target price on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a report on Friday. Scotiabank decreased their price objective on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a report on Friday. StockNews.com began coverage on Adaptimmune Therapeutics in a report on Friday. They issued a “buy” rating on the stock. Finally, Mizuho cut their target price on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a research report on Wednesday, November 27th.

Adaptimmune Therapeutics Price Performance

Shares of ADAP opened at $0.29 on Friday. The stock has a market cap of $74.41 million, a P/E ratio of -1.32 and a beta of 2.52. The business’s fifty day moving average is $0.54 and its 200 day moving average is $0.69. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a 12-month low of $0.26 and a 12-month high of $1.65.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Hedge funds have recently modified their holdings of the company. Invesco Ltd. grew its holdings in shares of Adaptimmune Therapeutics by 82.0% in the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 28,526 shares in the last quarter. Two Sigma Advisers LP boosted its position in Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 58,787 shares during the last quarter. Two Sigma Investments LP grew its stake in Adaptimmune Therapeutics by 33.5% in the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 19,146 shares during the period. Virtu Financial LLC increased its position in shares of Adaptimmune Therapeutics by 21.5% during the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 21,688 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in shares of Adaptimmune Therapeutics during the 3rd quarter worth $95,000. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.